A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)

NCT01802476 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Oral Drug Formulation of PD-0332991
DRUG: Intravenous Formulation of PD-0332991

Sponsor

Pfizer